The Food and Drug Administration on Monday rejected Akcea Therapeutics’ application to market Waylivra, its drug for familial chylomicronemia syndrome, in the United States.
Akcea didn’t give a reason for the rejection. Waylivra, also known as volanesorsen, would have been Akcea’s first drug in the U.S. market. The condition it treats, FCS, leads to a buildup of fat in organs.
About the Author Reprints
